Compare ALIT & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALIT | CRMD |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 958.1M |
| IPO Year | N/A | 2010 |
| Metric | ALIT | CRMD |
|---|---|---|
| Price | $1.90 | $11.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $5.25 | ★ $17.43 |
| AVG Volume (30 Days) | ★ 13.7M | 2.7M |
| Earning Date | 02-19-2026 | 11-12-2025 |
| Dividend Yield | ★ 8.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.25 |
| Revenue | ★ $2,289,000,000.00 | $214,303,672.00 |
| Revenue This Year | N/A | $627.89 |
| Revenue Next Year | $1.56 | $40.95 |
| P/E Ratio | ★ N/A | $5.41 |
| Revenue Growth | N/A | ★ 1647.67 |
| 52 Week Low | $1.82 | $5.60 |
| 52 Week High | $7.66 | $17.43 |
| Indicator | ALIT | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 34.62 | 46.23 |
| Support Level | $1.90 | $11.62 |
| Resistance Level | $2.00 | $13.02 |
| Average True Range (ATR) | 0.09 | 0.54 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 20.03 | 3.83 |
Alight Inc is a technology-enabled services company delivering human capital management solutions to many of complex organizations. This includes the implementation and administration of employee benefits (e.g., health, wealth and leaves benefits) solutions, currently operates under one reportable segment, Employer Solutions. The Company completed the Divestiture of Alight's Professional Services segment and Alight's Payroll & HCM Outsourcing business within the Employer Solutions segment. The company operates in USA states and International market too.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.